TissueScan, Ovarian Cancer cDNA Array II

Snippet: lected during debulking surgery. The identities of the patients from whom the pathological specimens were obtained remained anonymous. In addition, a commercial ovarian cancer cDNA was purchased from OriGene (Rockville, MD, USA) and used in this study. Detail information was summarized in Additional file 1: Tables S5 and S6. In vivo xenograft studies Animal experiments were conducted as previousl...

Snippet: validate that DNMT3B3 is overexpressed in advanced stages of HGSOC, we used two arrays of cDNA rapid cDNA panels: II and III, of ovarian carcinoma (TissueScan Ovarian Cancer cDNA arrays II and III) (OriGene Technologies, Rockville, MD, USA) (cat. no. HORT102 and 103), and both had 14 ovaries without cancer and 82 ovarian carcinoma samples of cDNA to be analyzed (Figure 4). 2.3. DNMT3B3 Overexpre

Snippet: …cDNA Measurements on Tissue cDNA Microarray SORT1 gene expression in a TissueScan ovarian cancer cDNA array II (OriGene, #HORT102, Rockville, MD, USA) was quantified by qPCR using SsoFast EvaGreen Supermix (Bio-Rad) in a CFX Connect Real-Time PCR System (Bio-Rad, Mississauga, ON, Canada). The relative quantit;SORT1 gene expression in a TissueScan ovarian cancer cDNA array II (OriGene, #HORT102, Rockville, MD, USA) was quantified by qPCR using SsoFast EvaGreen Supermix (Bio-Rad) in a CFX Connect Real-Time PCR System (Bio-Rad, Mississauga, ON, Canada)

Snippet: We probed the Origene human OvCa array for the presence of polymorphisms and gene expression alterations of GNAI2 using directing sequencing and qPCR.